Solit DB - Search Results

1

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Razavi P, et al. Among authors: solit db. Nat Cancer. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. Nat Cancer. 2020. PMID: 32864625 Free PMC article.

2

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Münster PN, Basso A, Solit D, Norton L, Rosen N. Münster PN, et al. Clin Cancer Res. 2001 Aug;7(8):2228-36. Clin Cancer Res. 2001. PMID: 11489796

3

Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors.

de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R. de Candia P, et al. Among authors: solit db. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12337-42. doi: 10.1073/pnas.2031337100. Epub 2003 Oct 2. Proc Natl Acad Sci U S A. 2003. PMID: 14526102 Free PMC article.

4

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

She QB, Solit D, Basso A, Moasser MM. She QB, et al. Clin Cancer Res. 2003 Oct 1;9(12):4340-6. Clin Cancer Res. 2003. PMID: 14555504

5

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.

Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK. Solit DB, et al. Cancer. 2003 Nov 1;98(9):1842-8. doi: 10.1002/cncr.11754. Cancer. 2003. PMID: 14584065 Free article. Clinical Trial.

6

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. Solit DB, et al. Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6. Nature. 2006. PMID: 16273091 Free PMC article.

7

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA. Fury MG, et al. Among authors: solit db. Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75. doi: 10.1007/s00280-006-0286-6. Epub 2006 Aug 1. Cancer Chemother Pharmacol. 2007. PMID: 16896930 Clinical Trial.

8

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. Among authors: solit db. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.

9

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB. Chandarlapaty S, et al. Among authors: solit db. Clin Cancer Res. 2008 Jan 1;14(1):240-8. doi: 10.1158/1078-0432.CCR-07-1667. Clin Cancer Res. 2008. PMID: 18172276 Free PMC article.

10

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB. Sawai A, et al. Among authors: solit db. Cancer Res. 2008 Jan 15;68(2):589-96. doi: 10.1158/0008-5472.CAN-07-1570. Cancer Res. 2008. PMID: 18199556 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters